RESUMEN
Schwannomatosis is the third form of neurofibromatosis and characterized by the occurrence of multiple schwannomas. The most prominent symptom is chronic pain. We aimed to test whether pain in schwannomatosis might be caused by small-fiber neuropathy. Twenty patients with schwannomatosis underwent neurological examination and nerve conduction studies. Levels of pain perception as well as anxiety and depression were assessed by established questionnaires. Quantitative sensory testing (QST) and laser-evoked potentials (LEP) were performed on patients and controls. Whole-body magnetic resonance imaging (wbMRI) and magnetic resonance neurography (MRN) were performed to quantify tumors and fascicular nerve lesions; skin biopsies were performed to determine intra-epidermal nerve fiber density (IENFD). All patients suffered from chronic pain without further neurological deficits. The questionnaires indicated neuropathic symptoms with significant impact on quality of life. Peripheral nerve tumors were detected in all patients by wbMRI. MRN showed additional multiple fascicular nerve lesions in 16/18 patients. LEP showed significant faster latencies compared to normal controls. Finally, IENFD was significantly reduced in 13/14 patients. Our study therefore indicates the presence of small-fiber neuropathy, predominantly of unmyelinated C-fibers. Fascicular nerve lesions are characteristic disease features that are associated with faster LEP latencies and decreased IENFD. Together these methods may facilitate differential diagnosis of schwannomatosis.
Asunto(s)
Fibras Nerviosas/patología , Neoplasias del Sistema Nervioso/etiología , Neuralgia/patología , Neurilemoma/complicaciones , Neurofibromatosis/complicaciones , Neoplasias Cutáneas/complicaciones , Adulto , Anciano , Dolor Crónico , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Mutación , Neoplasias del Sistema Nervioso/diagnóstico por imagen , Neuralgia/etiología , Neoplasias del Sistema Nervioso Periférico/diagnóstico por imagen , Neoplasias del Sistema Nervioso Periférico/etiología , Factores de Transcripción/genética , Imagen de Cuerpo EnteroRESUMEN
Primary brain tumors, both malignant and benign, are diagnosed in adults at an incidence rate of approximately 23 people per 100 thousand. The role of AhR in carcinogenesis has been a subject of debate, given that this protein may act as either an oncogenic protein or a tumor suppressor in different cell types and contexts. Lately, there is growing evidence that aryl hydrocarbon receptor (AhR) plays an important part in the development of brain tumors. The role of AhR in brain tumors is complicated, depending on the type of tumor, on ligands that activate AhR, and other features of the pathological process. In this review, we summarize current knowledge about AhR in relation to brain tumors and provide an overview of AhR's potential as a therapeutic target.
Asunto(s)
Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/genética , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/metabolismo , Neoplasias Encefálicas/etiología , Neoplasias Encefálicas/metabolismo , Susceptibilidad a Enfermedades , Receptores de Hidrocarburo de Aril/genética , Receptores de Hidrocarburo de Aril/metabolismo , Animales , Neoplasias Encefálicas/patología , Neoplasias Encefálicas/terapia , Manejo de la Enfermedad , Regulación Neoplásica de la Expresión Génica , Humanos , Quinurenina/metabolismo , Ligandos , Redes y Vías Metabólicas , Terapia Molecular Dirigida , Sistema Nervioso/metabolismo , Sistema Nervioso/patología , Neoplasias del Sistema Nervioso/etiología , Neoplasias del Sistema Nervioso/metabolismo , Neoplasias del Sistema Nervioso/patología , Transducción de Señal , Triptófano/metabolismoRESUMEN
Brain tumours that are refractory to treatment have a poor prognosis and constitute a major challenge in offering effective treatment strategies. By targeting molecular alterations, precision cancer medicine may be a viable option for the treatment of brain tumours. In this retrospective analysis of our PCM platform, we describe the molecular profiling of primary brain tumours from 50 patients. Tumour samples of the patients were examined by a 161-gene next-generation sequencing panel, immunohistochemistry, and fluorescence in situ hybridization (FISH). We identified 103 molecular aberrations in 36 (72%) of the 50 patients. The predominant mutations were TP53 (14.6%), IDH1 (9.7%) and PIK3CA (6.8%). No mutations were detected in 14 (28%) of the 50 patients. IHC demonstrated frequent overexpression of EGFR and mTOR, in 38 (76%) and 35 (70%) patients, respectively. Overexpression of PDGFRa and PDGFRb were less common and detected in 16 and four patients, respectively. For 35 patients a targeted therapy was recommended. In our database, the majority of patients displayed mutations, against which targeted therapy could be offered. Based on our observations, PCM may be a feasible novel treatment approach in neuro-oncology.
Asunto(s)
Neoplasias del Sistema Nervioso/diagnóstico , Neoplasias del Sistema Nervioso/terapia , Medicina de Precisión , Biomarcadores de Tumor , Susceptibilidad a Enfermedades , Estudio de Asociación del Genoma Completo , Humanos , Inmunohistoquímica , Hibridación Fluorescente in Situ , Oncología Médica/métodos , Neoplasias del Sistema Nervioso/etiología , Medicina de Precisión/métodosRESUMEN
Polyomavirus (PyV) infections are widespread in human populations and, although generally associated with silent persistence, rarely cause severe disease. Among diseases convincingly associated with natural PyV infections of humans, there are remarkably different tissue tropisms and outcomes, including progressive multifocal leukoencephalopathy, transient or progressive nephropathy, and cancer. The variable character and unpredictable outcomes of infection attest to large gaps in our basic understanding of PyV biology. In particular, the rich history of research demonstrating the oncogenic potential of PyVs in laboratory animals begs the question of why cancer is not more often associated with infection. Raccoon polyomavirus (RacPyV), discovered in 2010, is consistently identified in neuroglial tumors in free-ranging raccoons in the western United States. Exposure to RacPyV is widespread, and RacPyV is detected in tissues of raccoons without tumors. Studying the relationship of RacPyV with its natural host is a unique opportunity to uncover cogent cellular targets and protein interactions between the virus and its host. Our hypothesis is that RacPyV, as an intact episome, alters cellular pathways within neural progenitor cells and drives oncogenesis.
Asunto(s)
Neoplasias del Sistema Nervioso/veterinaria , Neuroglía/patología , Infecciones por Polyomavirus/veterinaria , Mapaches/virología , Infecciones Tumorales por Virus/virología , Animales , Antígenos Virales/inmunología , Carcinogénesis/patología , Interacciones Huésped-Patógeno , Neoplasias del Sistema Nervioso/etiología , Neoplasias del Sistema Nervioso/virología , Filogenia , Plásmidos , Poliomavirus/genética , Poliomavirus/inmunología , Infecciones por Polyomavirus/complicaciones , Infecciones por Polyomavirus/transmisión , Infecciones Tumorales por Virus/complicaciones , Infecciones Tumorales por Virus/transmisiónRESUMEN
Patients with von Hippel-Lindau disease carry a germline mutation of the Von Hippel-Lindau (VHL) tumor-suppressor gene. We discuss the molecular consequences of loss of VHL gene function and their impact on the nervous system. Dysfunction of the VHL protein causes accumulation and activation of hypoxia inducible factor (HIF) which can be demonstrated in earliest stages of tumorigenesis and is followed by expression of VEGF, erythropoietin, nitric oxide synthase and glucose transporter 1 in VHL-deficient tumor cells. HIF-independent functions of VHL, epigenetic inactivation of VHL, pVHL proteostasis, and links between loss of VHL function and developmental arrest are also described. A most intriguing feature in VHL disease is the occurrence of primary hemangioblastic tumors in the nervous system, the origin of which has not yet been entirely clarified, and current hypotheses are discussed. Endolymphatic sac tumors may extend into the brain, but originally arise from proliferation of endolymphatic duct/sac epithelium; the exact nature of the proliferating epithelial cell, however, also has remained unclear, as well as the question why tumors almost consistently develop in the intraosseous portion of the endolymphatic sac/duct only. The epitheloid clear cell morphology of both advanced hemangioblastoma and renal clear cell carcinoma can make the differential diagnosis challenging, recent developments in immunohistochemical differentiation are discussed. Finally, metastasis to brain may not only be caused by renal carcinoma, but may derive from VHL disease-associated pheochromocytoma/paraganglioma, or pancreatic neuroendocrine tumor.
Asunto(s)
Neoplasias del Sistema Nervioso/patología , Sistema Nervioso/patología , Enfermedad de von Hippel-Lindau/patología , Animales , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/genética , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/metabolismo , Saco Endolinfático/patología , Hemangioblastoma/complicaciones , Hemangioblastoma/etiología , Hemangioblastoma/patología , Humanos , Sistema Nervioso/fisiopatología , Neoplasias del Sistema Nervioso/etiología , Neuroimagen , Proteína Supresora de Tumores del Síndrome de Von Hippel-Lindau/metabolismo , Enfermedad de von Hippel-Lindau/complicaciones , Enfermedad de von Hippel-Lindau/genética , Enfermedad de von Hippel-Lindau/metabolismoAsunto(s)
Teléfono Celular/legislación & jurisprudencia , Campos Electromagnéticos/efectos adversos , Neoplasias del Sistema Nervioso/etiología , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Neoplasias Encefálicas/etiología , Neoplasias de los Nervios Craneales/etiología , Glioma/etiología , Humanos , Incidencia , Italia/epidemiología , Neoplasias del Sistema Nervioso/epidemiología , Neuroma/etiologíaRESUMEN
INTRODUCTION: Thrombosis and infections are well known complications of central venous catheters and totally implanted access ports. These complications lead to increased costs due to prolonged hospitalisation, increased antibiotics use and need for replacement. The objectives of the study were to document the occurrence of catheter related thrombosis and infections in patients with central venous catheters and totally implanted chest ports in cancer patients and to investigate whether factor V Leiden is a risk factor for catheter related thrombosis. MATERIALS AND METHODS: Between February 2002 and November 2004, 43 patients with central venous catheter or totally implanted access port were followed up to document the occurrence of catheter related thrombosis and infections. Patients received chemotherapy either for haematological malignancy or for solid tumours. Factor V Leiden (R506Q) was determined by restriction fragment length polymorphism analysis. Follow-up period ended in April 2007. RESULTS: Catheter related thrombosis occurred in 4 patients (4/43; 9.3%) with a totally implanted access port. None of the 3 patients with factor V Leiden had catheter related infection or thrombosis. Catheter related infections occurred in 15 patients: 10 patients (23.3%; 10/43) with central venous catheter and 5 patients (11.6%; 5/43) with totally implanted access ports. Time to infection was 32.5 days in the central venous catheter group compared to 88 days in the totally implanted access port group. CONCLUSION: A higher incidence of catheter related infections was observed in patients with central venous catheters in contrast to patients with totally implanted access ports were venous thrombosis was more frequent.
Asunto(s)
Cateterismo Venoso Central/efectos adversos , Cateterismo/efectos adversos , Infecciones/etiología , Neoplasias/tratamiento farmacológico , Trombosis/etiología , Trombosis de la Vena/etiología , Antibacterianos/uso terapéutico , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/tratamiento farmacológico , Neoplasias Hematológicas/etiología , Humanos , Incidencia , Infecciones/complicaciones , Infecciones/tratamiento farmacológico , Neoplasias/complicaciones , Neoplasias/etiología , Neoplasias del Sistema Nervioso/complicaciones , Neoplasias del Sistema Nervioso/tratamiento farmacológico , Neoplasias del Sistema Nervioso/etiología , Pacientes , Factores de Riesgo , Trombosis/complicaciones , Trombosis/tratamiento farmacológico , Venas , Trombosis de la Vena/complicaciones , Trombosis de la Vena/tratamiento farmacológicoRESUMEN
Neurofibromatosis type 2 is an autosomal-dominant multiple neoplasia syndrome that results from mutations in the NF2 tumour suppressor gene located on chromosome 22q. It has a frequency of one in 25,000 livebirths and nearly 100% penetrance by 60 years of age. Half of patients inherit a germline mutation from an affected parent and the remainder acquire a de novo mutation for neurofibromatosis type 2. Patients develop nervous system tumours (schwannomas, meningiomas, ependymomas, astrocytomas, and neurofibromas), peripheral neuropathy, ophthalmological lesions (cataracts, epiretinal membranes, and retinal hamartomas), and cutaneous lesions (skin tumours). Optimum treatment is multidisciplinary because of the complexities associated with management of the multiple, progressive, and protean lesions associated with the disorder. We review the molecular pathogenesis, genetics, clinical findings, and management strategies for neurofibromatosis type 2.
Asunto(s)
Neurofibromatosis 2 , Catarata/etiología , Cromosomas Humanos Par 22/genética , Progresión de la Enfermedad , Frecuencia de los Genes/genética , Genes de la Neurofibromatosis 2 , Pruebas Genéticas , Humanos , Biología Molecular , Mutación/genética , Neoplasias del Sistema Nervioso/etiología , Neurofibromatosis 2/diagnóstico , Neurofibromatosis 2/epidemiología , Neurofibromatosis 2/genética , Neurofibromatosis 2/terapia , Neurofibromina 2/genética , Grupo de Atención al Paciente/organización & administración , Linaje , Penetrancia , Enfermedades del Sistema Nervioso Periférico/etiología , Neoplasias Cutáneas/etiología , Tasa de SupervivenciaRESUMEN
Neuroblastoma (NB), a tumor of the sympathetic nervous system, is the most common infant malignancy. The etiology of NB is largely unknown. We explored the association between birth record variables and subsequent NB development in a population-based case-cohort study in Minnesota by linking the birth and cancer registries. NB cases included 155 children born during 1976-2004 who were diagnosed from 28 days through 14 years of age. The comparison group included 8,752 individuals randomly sampled from the birth cohort of cases. Cox proportional hazards regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Controlling for birth year and sex, maternal history of one fetal loss (HR = 1.7, 95% CI 1.2-2.5), maternal prenatal drug-use (recorded starting in 1992) (HR = 5.7, 95% CI 2.3-14) and child's small size for gestational age (HR = 2.1, 95% CI 1.1-4.0) were significantly associated with NB. Age group specific analyses indicated that maternal hypertension (HR = 3.0, 95% CI 1.3-7.2) and maternal age <20 years (HR = 2.6, 95% CI 1.1-6.1) increased risks for infant NB only. Our study provides evidence that a few perinatal exposures as recorded in birth records may play a role in NB etiology.
Asunto(s)
Neoplasias del Sistema Nervioso/etiología , Neuroblastoma/etiología , Sistema Nervioso Simpático , Aborto Espontáneo , Adolescente , Estudios de Casos y Controles , Niño , Preescolar , Femenino , Humanos , Hipertensión , Lactante , Recién Nacido , Recién Nacido Pequeño para la Edad Gestacional , Masculino , Edad Materna , Madres , Oportunidad Relativa , Embarazo , Efectos Tardíos de la Exposición Prenatal , Modelos de Riesgos Proporcionales , Factores de Riesgo , Trastornos Relacionados con SustanciasRESUMEN
OBJECTIVES: Epidemiological studies have reported associations between childhood cancer and either parental or child exposure to pesticides. Reviews have been published in 1997, 1998 and 2006 where the evidence was found suggestive but not conclusive. The present review is an extended update of the latter one. METHODS: The PubMed database was searched to identify published studies on this topic issued between 1998 and 2006. RESULTS: Thirty-six new studies have been identified for this review. Some cohort studies and the majority of the case-control studies suggest an increased risk for the cancer types studied, associated with exposure to pesticides in at least one of a large variety of exposure categories. However, the evidence is conflicting with regard to cancer types as well as to causative factors across studies. The major shortcomings concern exposure assessment, where, e. g., "farming" is treated equal to "exposure to pesticides", disregarding other possible exposures, e.g., to biological or infectious agents, and hitherto unidentified lifestyle factors. Also, many exposure categories used, mainly in case-control studies, lack chemical or toxicological plausibility. In most studies exposures were categorized as "ever vs. never", with little regard of exposure intensity or duration. CONCLUSIONS: The available literature does not allow firm conclusions with regard to pesticides and any type of childhood cancer. But even if the reported associations were true, exposure to pesticides could not explain the vast majority of childhood cancer cases. Investing in the acquisition and critical review of exposure information appears to be the crucial step for causal assessment in future research. However, focusing on the presence of pesticides, and not asking the question why they were used, might mask relevant associations to other causative agents.
Asunto(s)
Neoplasias/etiología , Plaguicidas/envenenamiento , Niño , Humanos , Neoplasias Renales/etiología , Leucemia/etiología , Linfoma/etiología , Neoplasias del Sistema Nervioso/etiologíaRESUMEN
Tumors of the nervous system most often occur in both children and adults as sporadic events with no family history of the disease, but they are also among the clinical manifestations of a significant number of familial cancer syndromes, including familial retinoblastoma, neurofibromatosis 1 and 2, tuberous sclerosis, and Cowden, Turcot, Li-Fraumeni and nevoid basal cell carcinoma (Gorlin) syndromes. All of these syndromes involve transmissible genetic risk resulting from loss of a functional allele, or inheritance of a structurally defective allele, of a specific gene. These genes include RB1, NF1, NF2, TSC1, TSC2, TP53, PTEN, APC, hMLH1, hPSM2, and PTCH, most of which function as tumor suppressor genes. The same genes are also observed in mutated and inactive forms, or are deleted, in tumor cells in sporadic cases of the same tumors. The nature of the mutational events that give rise to these inactivated alleles suggests a possible role of environmental mutagens in their causation. However, only external ionizing radiation at high doses is clearly established as an environmental cause of brain, nerve and meningeal tumors in humans. Transplacental carcinogenesis studies in rodents and other species emphasize the extraordinary susceptibility of the developing mammalian nervous system to carcinogenesis, but the inverse relationship of latency to dose suggests that low transplacental exposures to genotoxicants are more likely to result in brain tumors late in life, rather than in childhood. While not all neurogenic tumor-related genes in humans have similar effects in experimental rodents, genetically engineered mice (GEM) increasingly provide useful insights into the combined effects of multiple tumor suppressor genes and of gene-environment interactions in the genesis of brain tumors, especially pediatric brain tumors such as medulloblastoma.
Asunto(s)
Neoplasias del Sistema Nervioso/genética , Adulto , Animales , Secuencia de Bases , Niño , ADN de Neoplasias/genética , Femenino , Genes Supresores de Tumor , Genes erbB-2 , Humanos , Ratones , Ratones Transgénicos , Mutación , Neoplasias del Sistema Nervioso/etiología , Oncogenes , Embarazo , SíndromeRESUMEN
This review article provides guidelines for the diagnosis, staging, and management of primary nervous system lymphoma based on the results of clinical trials conducted during the last decade. Recent progress in our understanding of the pathogenesis of primary nervous system lymphoma is summarized, and implications of these findings for the development of diagnostic tools and new therapeutic strategies are outlined. We performed a search of the PubMed database (National Center for Biotechnology Information) for articles on primary nervous system lymphoma published between 1970 and May 2005. Primary nervous system lymphoma affects the brain, eye, and meninges as well as cranial, spinal, and peripheral nerves. Although important lessons have been learned from the pathogenesis of extraneural non-Hodgkin's lymphoma, the unique organotropism of primary nervous system lymphoma remains poorly understood. Diagnosis is facilitated by modern imaging techniques and molecular markers. Clinically recognizable "precursors" may exist but frequently elude specific diagnosis. Insight into the peculiar pharmacokinetics of chemotherapy aimed at tumors within the nervous system has led to the development of methotrexate-based regimens that can achieve prolonged progression-free survival without the use of radiation. Long-term survival and, in selected cases, even a cure are possible in primary nervous system lymphoma. Treatment should be provided in specialized multidisciplinary centers. In spite of remarkable progress through methotrexate-based chemotherapy, the majority of patients experience relapse within a few years. Better diagnostic tools are required for earlier diagnosis and monitoring of treatment response. A deeper understanding of the pathogenesis of primary nervous system lymphoma may reveal new therapeutic targets.
Asunto(s)
Linfoma no Hodgkin/diagnóstico , Linfoma no Hodgkin/terapia , Neoplasias del Sistema Nervioso/diagnóstico , Neoplasias del Sistema Nervioso/terapia , Antimetabolitos Antineoplásicos/uso terapéutico , Terapia Combinada , Neoplasias del Ojo/terapia , Humanos , Linfoma Relacionado con SIDA/terapia , Linfoma no Hodgkin/epidemiología , Linfoma no Hodgkin/etiología , Imagen por Resonancia Magnética , Metotrexato/uso terapéutico , Neoplasias del Sistema Nervioso/epidemiología , Neoplasias del Sistema Nervioso/etiología , Trasplante de Órganos , RadioterapiaRESUMEN
OBJECTIVES: In Europe and the United States, cancer is a major cause of death among children aged 5-14 years. The role of environmental exposure to pesticides in carcinogenesis, although strongly postulated, is still unknown. Pesticides have been used since the early days of modern agriculture. They are biologically active compounds, which may pose health risk during or after their use. MATERIALS AND METHODS: Epidemiological studies focused on childhood cancer and exposure to pesticides, conducted over the last seven years, were identified through searching PUBMED, MEDLINE and EBSCO literature bases. From each study, the following information was abstracted: type of cancer, type of exposure, study design, risk estimate, and study population. This review will try to answer the question on whether any further progress in epidemiology of childhood cancer due to pesticide exposure has been made. RESULTS: Leukemia, brain cancer, non-Hodgkin's lymphoma and neuroblastoma are mentioned as potentially associated with pesticide exposure among children. Despite an increasing evidence in support of this finding, it is still limited because of the weakness of research methodology. The substantial weak points of numerous epidemiological studies of pesticide-related health effects are problems faced in exposure assessment, small numbers of exposed subjects, a limited number of studies focused on the majority of cancers, and difficulties in estimating critical windows of exposure. CONCLUSION: In the light of existing, although still limited evidence of adverse effects of pesticide exposure, it is necessary to reduce exposure to pesticides. The literature review suggests a great need to increase awareness among people occupationally or environmentally exposed to pesticides about their potential negative influence on health of their children.
Asunto(s)
Exposición a Riesgos Ambientales , Neoplasias/epidemiología , Plaguicidas/toxicidad , Adolescente , Neoplasias Encefálicas/epidemiología , Neoplasias Encefálicas/etiología , Niño , Preescolar , Estudios Epidemiológicos , Humanos , Leucemia/epidemiología , Leucemia/etiología , Linfoma no Hodgkin/epidemiología , Linfoma no Hodgkin/etiología , Neoplasias/etiología , Neoplasias del Sistema Nervioso/epidemiología , Neoplasias del Sistema Nervioso/etiología , Neuroblastoma/epidemiología , Neuroblastoma/etiología , Factores de Riesgo , Tumor de Wilms/epidemiología , Tumor de Wilms/etiologíaAsunto(s)
Neoplasia Endocrina Múltiple Tipo 1/diagnóstico , Neoplasia Endocrina Múltiple Tipo 1/patología , Neoplasias del Sistema Nervioso/etiología , Lesiones Precancerosas/diagnóstico , Lesiones Precancerosas/patología , Proteínas Proto-Oncogénicas/genética , Predisposición Genética a la Enfermedad , Humanos , Modelos Biológicos , Mutación , Proteínas Proto-Oncogénicas/fisiología , Factores de RiesgoRESUMEN
Neurofibromatosis type 1 (NF1) is the most common of all the phakomatoses. It is an autosomal dominant disorder, with about 50% of patients being new mutations. NF1 is diagnosed based on the presence of well established diagnostic criteria. Prominent cutaneous manifestations include cafe-au-lait spots, freckling and cutaneous neurofibromas. CNS lesions are frequent and imaging is valuable for diagnosis, treatment and follow-up of patients. Tumors of the central nervous system are frequent. Optic nerve glioma usually affects younger patients with clinical symptoms in one third of cases. MRI shows fusiform enlargement with variable enhancement of the optic nerve. These tumors are usually non-aggressive with good prognosis. Other gliomas and astrocytomas can occur as well, usually midline in location, that also generally have good prognosis. Non-tumoral white matter lesions, referred as unidentified bright objects or UBO's, are frequently observed, typically in the basal ganglia and posterior fossa structures. These lesions are usually seen during childhood and they typically diminish with age. The distinction between UBO's and other tumors may be difficult to achieve at imaging, and a malignant evolution may very rarely be observed. Patients with NF1 may have hydrocephalus and dural sac anomalies leading to meningocele formation. Neurofibromas and plexiform neurofibromas involve peripheral nerves and nerve sheaths. Plexiform neurofibromas may cause radicular symptoms. They more frequently involve the lumbosacral plexus. Neurofibromas are homogeneous oval shaped tumors that may extend into the spinal canal. Neurofibrosarcoma is the main cause of death of NF1 patients less than 40 years of age. It may develop de novo or from sarcomatous degeneration of a pre-existing plexiform neurofibroma. It should be suspected in patients with new onset of symptoms or patients with changing symptoms. At imaging, it is characterized by a large heterogeneous tumor invading adjacent structures. Osseous lesions have been described including progressive thoracic scoliosis, vertebral anomalies (posterior scalloping is very suggestive), long bones anomalies with frequent bowing of the tibia, sometimes resulting in pseudarthrosis, and rib anomalies with ribbon ribs. Vascular lesions may occur resulting in arterial hypertension and aneurysm formation.
Asunto(s)
Neoplasias del Sistema Nervioso/patología , Neurofibromatosis 1/patología , Neoplasias Óseas/etiología , Neoplasias Óseas/patología , Manchas Café con Leche/etiología , Manchas Café con Leche/patología , Humanos , Imagen por Resonancia Magnética , Neoplasias del Sistema Nervioso/etiología , Neurofibromatosis 1/complicacionesRESUMEN
Germ line and somatic mutations in the neurofibromatosis Type 2 (NF2) tumor suppressor gene predispose individuals to tumors of the nervous system, including schwannomas and meningiomas. Since identification of the NF2 gene more than a decade ago, a large body of information has been collected on the nature and consequences of these alterations in patients with NF2 and in individuals in whom sporadic tumors associated with NF2 develop. The catalog of mutations identified thus far has facilitated extensive genetic analysis, including studies of patients with mosaicism and phenotype-genotype correlations, and has also led to experiments that have begun to unravel the molecular biology of the NF2 gene and its role in tumorigenesis. The authors describe some of the most significant findings in NF2 genetics and biology over the last decade.
Asunto(s)
Genes de la Neurofibromatosis 2/fisiología , Neoplasias del Sistema Nervioso/genética , Neurofibromatosis 2/genética , Animales , Humanos , Neoplasias del Sistema Nervioso/etiología , Neurofibromatosis 2/etiologíaRESUMEN
We used the nationwide Swedish Family-Cancer Database to analyze the risk for nervous system tumors in offspring through parental and sibling probands. Among 0-68-year-old offspring, close to 11000 patients with a nervous system tumor were identified in years 1961 to 2000, among whom 199 had a parent diagnosed with a nervous system tumor. Brain tumors constituted 86% of all tumors, and astrocytoma was the main histological type, representing half of all cases. Standardized incidence ratios (SIRs) for familial risk were only increased for brain tumors of meningioma, astrocytoma, and hemangioblastoma histology. When parents were diagnosed with tumors of the same histology, the SIRs for offspring were 3.06, 2.19, and 165 for meningioma, astrocytoma, and hemangioblastoma, respectively. Among siblings, the SIRs were 4.41, 3.20, and 61. Age-specific analysis of familial astrocytoma revealed three distinct components, one < 10 years, the second approximately age 30 years, and the third at age >60 years. The kappa test was used to assess the likelihood of an identical histology in two family members. The occurrence of hemangioblastoma was completely determined among the siblings, and the kappa value was 1.00. Meningiomas were also moderately ordered among the siblings, but astrocytomas were less determined. Many syndromes are known in which nervous system tumors are manifestations, including hemangioblastoma, recognized as part of von Hippel-Lindau disease. Yet, it is likely that many brain astrocytoma, meningioma, and mixed families represent yet unknown heritable conditions.
Asunto(s)
Astrocitoma/genética , Neoplasias Encefálicas/genética , Bases de Datos Factuales , Meningioma/genética , Neoplasias del Sistema Nervioso/genética , Adolescente , Adulto , Anciano , Astrocitoma/etiología , Neoplasias Encefálicas/etiología , Niño , Preescolar , Estudios Epidemiológicos , Humanos , Lactante , Recién Nacido , Meningioma/etiología , Persona de Mediana Edad , Neoplasias del Sistema Nervioso/etiología , Linaje , Estudios Retrospectivos , Factores de Riesgo , Suecia/epidemiologíaRESUMEN
The mechanisms of carcinogenesis in nervous tissues are not well understood. It is now established that adenosine 3,',5'-cyclic monophosphate (cAMP)-pathway plays a crucial role in initiating differentiation in transformed and embryonic cells of neuronal and glial origin. Therefore, we propose that defects in the cAMP-pathway may initiate the first phase of carcinogenesis (immortalization). Subsequent genetic abnormalities in oncogenes, anti-oncogenes or other cellular genes individually or in combination may lead to transformation (cancer phenotype). This hypothesis is derived from the fact that an elevation of the cAMP level in murine NB cells induces terminal differentiation in many of these cells in spite of the fact that they are highly aneuploid. Additional changes in cAMP-regulated genes responsible for initiating differentiation may make these cells resistant to cAMP or may make the cAMP-effect on differentiation reversible. Indeed, cAMP-resistant cells exist in NB cell populations, and the cAMP-effect on differentiation is reversible in glioma cells. Identification of genes that initiate, promote and maintain terminal differentiation and those which prevent differentiation following elevation of cAMP in NB cells may increase our understanding of the mechanisms of carcinogenesis. This review illustrates the following: (a) historical background leading to the discovery of cAMP as an inducer of differentiation in nerve cells; (b) identification of potential sites in cAMP-pathway that may play a crucial role in initiating the first phase of carcinogenesis (immortalization) and potential gene targets in immortalized cells whose alterations may cause neoplastic transformation of nerve cells. It is interesting to note that the cAMP pathway remains responsive to an elevated cAMP level in inducing differentiation in NB cells in spite of chromosomal anomalies and genetic changes associated with the maintenance of a cancer phenotype.